Skip to main content

Month: September 2020

Beyond Meat, Inc. Announces Historic Agreement to Bring Production of Plant-Based Meat for the China Market to Jiaxing EDZ, China, a Strategic Location Near Shanghai

SHANGHAI, China, Sept. 08, 2020 (GLOBE NEWSWIRE) — Beyond Meat (Jiaxing) Food Co., Ltd., a wholly-owned subsidiary of Beyond Meat, Inc. (NASDAQ: BYND), has signed an agreement with Jiaxing Economic & Technological Development Zone (JXEDZ) to design and develop manufacturing facilities in the JXEDZ, including a state-of-the-art production facility to manufacture plant-based meat products including beef, pork and chicken under the Beyond Meat brand in China. The production facilities will be located in the JXEDZ, a historic and commercially important development zone with ready access to Shanghai.Beyond Meat, Inc. will be the first multinational company focused solely on plant-based meat production to bring its own major production facility into China.Micky Pant, Senior Advisor to Beyond Meat said: “Beyond Meat is building...

Continue reading

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (“pMDI”) formulation in U.S. patients hospitalized with COVID-19.The study will evaluate the effect of ensifentrine on key outcomes in patients hospitalized with COVID-19 including facilitation of recovery from the viral infection, clinical status improvement and reduction in supplemental oxygen use and progression to mechanical ventilation.Ensifentrine is a first-in-class product candidate that combines bronchodilator and anti-inflammatory activities in one compound. Clinical data from studies...

Continue reading

Jobindex får støtte af Innovationsfonden

Der er godt nyt til de mange danskere, der årligt navigerer i jobsøgningsjunglen. Et nyt 3-årigt forskningsprojekt går nu i gang med at knække koden til at matche jobsøgende med de rigtige job. Projektet bliver støttet af Innovationsfonden med 7 mio. kr. KU, AAU og Jobindex vil matche jobsøgende med de rigtige jobIngen er hidtil lykkedes med at designe den perfekte algoritme til at lave gode jobmatch. Den udfordring vil forskere på Københavns Universitet og Aalborg Universitet forsøge at løse i samarbejde med it- og rekrutteringsvirksomheden Jobindex. Nøglen til det nye system er unikke data fra de omtrent 100.000 stillinger, som Jobindex’ jobkonsulenter har matchet manuelt over de sidste 10 år. Dem skal forskerne bruge til at give systemet viden om hvilke personlige egenskaber og faglige evner, der passer bedst til hvilke stillinger. Det...

Continue reading

OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September 14 – 16, 2020 (Virtual Conference)

NANTES, France, Sept. 08, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced it will present at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held virtually on September 14 – 16, 2020.  Alexis Peyroles, CEO of OSE Immunotherapeutics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.Event: ...

Continue reading

Investment Outlook: Back to the future

The stock market has had a dramatic year. After a strong start, it plunged at record speed by more than 30 per cent. Since then it has shown a very strong performance, with very few corrections given the great uncertainty prevailing about the coronavirus pandemic, economic growth and politics.    

Continue reading

Innate Pharma Reports First Half 2020 Financial Results and Business Update

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoidesMonalizumab Phase 3 study expected to initiate in the second half of 2020, triggering $50 million milestone paymentInnate to explore avdoralimab in inflammation beyond COVID-19Cash position of €184.6 million1 as of June 30, 2020MARSEILLE, France, Sept. 08, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2020. The consolidated financial statements are attached to this press release.“In the first half of 2020, Innate has made meaningful progress across its portfolio, quickly resuming enrollment in the lacutamab Phase 2 study, TELLOMAK, for patients...

Continue reading

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

 Geneva, Switzerland and Boston, MA –  September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the H.C Wainwright 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020.Mr. Loumaye’s presentation will take place on Wednesday September 16 at 12:00 p.m. Eastern Time (ET).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.comAbout ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined...

Continue reading

Uxin Reports Unaudited First Quarter of Fiscal Year 2021 Financial Results

BEIJING, Sept. 08, 2020 (GLOBE NEWSWIRE) — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), a leading national online used car dealer in China, today announced its unaudited financial results for the quarter ended June 30, 2020.Highlights for the Quarter Ended June 30, 20202C transaction volume was 3,887 units for the three months ended June 30, 2020, compared with 24,585 in the same period last year.2C GMV1 was RMB426 million for the three months ended June 30, 2020, compared with RMB2,864 million in the same period last year.Total revenues were RMB62.2 million (US$8.8 million) for the three months ended June 30, 2020, compared with RMB389.3 million in the same period last year.2C revenue was RMB51.7 million (US$7.3 million) for the three months ended June 30, 2020, compared with RMB341.0 million in the same period last year.Gross...

Continue reading

Suncor Energy provides operational and 2020 guidance update

All financial figures are in Canadian dollars.CALGARY, Alberta, Sept. 07, 2020 (GLOBE NEWSWIRE) — Following the August 14 incident at its Base Plant operations, in light of identified performance improvement opportunities at its Firebag operation, and bringing on the second train of production at Fort Hills, Suncor is today providing an operational update and revised 2020 guidance.On August 16, 2020, Suncor reported it had experienced a fire at the secondary extraction facilities of its Base Plant mine.  On August 29th, production was restored to 165,000 barrels per day (bbls/d) of mined bitumen. Although initial repairs can allow the mine to operate at full rates, production has been restricted to manage bitumen quality into the upgraders.  Production is expected to continue to ramp up and will achieve full mining rates of approximately...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.